ID:KIF11_HUMAN DESCRIPTION: RecName: Full=Kinesin-like protein KIF11; AltName: Full=Kinesin-like protein 1; AltName: Full=Kinesin-like spindle protein HKSP; AltName: Full=Kinesin-related motor protein Eg5; AltName: Full=Thyroid receptor-interacting protein 5; Short=TR-interacting protein 5; Short=TRIP-5; FUNCTION: Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays. SUBUNIT: Interacts with the thyroid hormone receptor in the presence of thyroid hormone. Component of a large chromatin remodeling complex, at least composed of MYSM1, PCAF, RBM10 and KIF11/TRIP5. Interacts (via C-terminus) with the kinase NEK6 in both interphase and mitosis. SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. PTM: Phosphorylated exclusively on serine during S phase, but on both serine and Thr-926 during mitosis, so controlling the association of KIF11 with the spindle apparatus (probably during early prophase). Phosphorylated upon DNA damage, probably by ATM or ATR. PTM: A subset of this protein primarily localized at the spindle pole is phosphorylated by NEK6 during mitosis; phosphorylation is required for mitotic function. DISEASE: Defects in KIF11 are the cause of microcephaly with or without chorioretinopathy, lymphedema, or mental retardation (MCLMR) [MIM:152950]. An autosomal dominant disorder that involves an overlapping but variable spectrum of central nervous system and ocular developmental anomalies. Microcephaly ranges from mild to severe and is often associated with mild to moderate developmental delay and a characteristic facial phenotype with upslanting palpebral fissures, broad nose with rounded tip, long philtrum with thin upper lip, prominent chin, and prominent ears. Chorioretinopathy is the most common eye abnormality, but retinal folds, microphthalmia, and myopic and hypermetropic astigmatism have also been reported, and some individuals have no overt ocular phenotype. Congenital lymphedema, when present, is typically confined to the dorsa of the feet, and lymphoscintigraphy reveals the absence of radioactive isotope uptake from the webspaces between the toes. SIMILARITY: Belongs to the kinesin-like protein family. BimC subfamily. SIMILARITY: Contains 1 kinesin-motor domain.
The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.
ModBase Predicted Comparative 3D Structure on P52732
Front
Top
Side
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.
Orthologous Genes in Other Species
Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
BC050421 - Homo sapiens kinesin family member 11, mRNA (cDNA clone IMAGE:6471737). AK314258 - Homo sapiens cDNA, FLJ95005, highly similar to Homo sapiens kinesin family member 11 (KIF11), mRNA. BC136474 - Homo sapiens kinesin family member 11, mRNA (cDNA clone MGC:168086 IMAGE:9020463), complete cds. BC126211 - Homo sapiens kinesin family member 11, mRNA (cDNA clone MGC:161489 IMAGE:8991927), complete cds. U37426 - Human kinesin-like spindle protein HKSP (HKSP) mRNA, complete cds. X85137 - H.sapiens mRNA for kinesin-related protein. BC050667 - Homo sapiens, clone IMAGE:6013224, mRNA. JD174189 - Sequence 155213 from Patent EP1572962. HV496035 - JP 2011518117-A/1263: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401552 - JP 2015177801-A/1263: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496019 - JP 2011518117-A/1247: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401536 - JP 2015177801-A/1247: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496037 - JP 2011518117-A/1265: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401554 - JP 2015177801-A/1265: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496015 - JP 2011518117-A/1243: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401532 - JP 2015177801-A/1243: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496022 - JP 2011518117-A/1250: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401539 - JP 2015177801-A/1250: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496023 - JP 2011518117-A/1251: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401540 - JP 2015177801-A/1251: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496025 - JP 2011518117-A/1253: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401542 - JP 2015177801-A/1253: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496024 - JP 2011518117-A/1252: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401541 - JP 2015177801-A/1252: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496026 - JP 2011518117-A/1254: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401543 - JP 2015177801-A/1254: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496027 - JP 2011518117-A/1255: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401544 - JP 2015177801-A/1255: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496033 - JP 2011518117-A/1261: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401550 - JP 2015177801-A/1261: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496028 - JP 2011518117-A/1256: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401545 - JP 2015177801-A/1256: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496018 - JP 2011518117-A/1246: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401535 - JP 2015177801-A/1246: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496031 - JP 2011518117-A/1259: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401548 - JP 2015177801-A/1259: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496017 - JP 2011518117-A/1245: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401534 - JP 2015177801-A/1245: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496036 - JP 2011518117-A/1264: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401553 - JP 2015177801-A/1264: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496034 - JP 2011518117-A/1262: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401551 - JP 2015177801-A/1262: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496021 - JP 2011518117-A/1249: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401538 - JP 2015177801-A/1249: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HV496032 - JP 2011518117-A/1260: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401549 - JP 2015177801-A/1260: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. AB208964 - Homo sapiens mRNA for kinesin family member 11 variant protein. HV496030 - JP 2011518117-A/1258: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. HZ401547 - JP 2015177801-A/1258: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES. L40372 - Homo sapiens thyroid receptor interactor (TRIP5) mRNA, partial cds. JD564395 - Sequence 545419 from Patent EP1572962. JD558319 - Sequence 539343 from Patent EP1572962. JD558320 - Sequence 539344 from Patent EP1572962. JD540189 - Sequence 521213 from Patent EP1572962. JD560096 - Sequence 541120 from Patent EP1572962. JD356975 - Sequence 337999 from Patent EP1572962. JD395749 - Sequence 376773 from Patent EP1572962. JD217791 - Sequence 198815 from Patent EP1572962. JD520606 - Sequence 501630 from Patent EP1572962. JD144545 - Sequence 125569 from Patent EP1572962. JD084352 - Sequence 65376 from Patent EP1572962. JD247768 - Sequence 228792 from Patent EP1572962. JD326810 - Sequence 307834 from Patent EP1572962. JD430125 - Sequence 411149 from Patent EP1572962. JD557297 - Sequence 538321 from Patent EP1572962. JD529107 - Sequence 510131 from Patent EP1572962. JD169179 - Sequence 150203 from Patent EP1572962. JD169180 - Sequence 150204 from Patent EP1572962. JD041215 - Sequence 22239 from Patent EP1572962. JD320963 - Sequence 301987 from Patent EP1572962. JD387940 - Sequence 368964 from Patent EP1572962. JD387941 - Sequence 368965 from Patent EP1572962. JD118022 - Sequence 99046 from Patent EP1572962. JD292784 - Sequence 273808 from Patent EP1572962. JD080893 - Sequence 61917 from Patent EP1572962. JD177398 - Sequence 158422 from Patent EP1572962. JD188571 - Sequence 169595 from Patent EP1572962. JD303815 - Sequence 284839 from Patent EP1572962. JD401939 - Sequence 382963 from Patent EP1572962. JD060936 - Sequence 41960 from Patent EP1572962. JD053502 - Sequence 34526 from Patent EP1572962. JD330403 - Sequence 311427 from Patent EP1572962. JD382197 - Sequence 363221 from Patent EP1572962. JD328833 - Sequence 309857 from Patent EP1572962. JD173149 - Sequence 154173 from Patent EP1572962. JD283538 - Sequence 264562 from Patent EP1572962. JD348490 - Sequence 329514 from Patent EP1572962. JD196745 - Sequence 177769 from Patent EP1572962. JD312991 - Sequence 294015 from Patent EP1572962.
Biochemical and Signaling Pathways
Reactome (by CSHL, EBI, and GO)
Protein P52732 (Reactome details) participates in the following event(s):